KOVAI · NSE
Kovai Medical Center & Hospital Limited
₹6,226
+1.87% (+₹114)
Prev. close
₹6,112
Volume
3,229
Delivery %
66.2%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Kovai Medical Center & Hospital Limited
Kovai Medical Center and Hospital Limited operates a multispecialty hospital and its satellite centers in India. It operates through two segments, Healthcare Services and Education Services. The company offers outpatient and inpatient medical services in the fields of cardiology, cardiac anesthesiology, cardiovascular and thoracic surgery, comprehensive cancer center, critical care medicine, dentistry/faciomaxillary surgery, dermatology and cosmetic dermatology, electrophysiology, emergency services, endocrinology and diabetology, ENT/head and neck, fertility and reproductive medicine, gastroenterology and hepatology, general/laparoscopic surgery, hematology, internal medicine, interventional radiology, liver institute, laboratory medicine, neonatology, nephrology/urology, neurosciences, nuclear medicine and PET CT, obstetrics and gynecology, organ transplant program, orthopedics and joint replacement, pediatrics, pediatric surgery, pediatric intensive care unit, physical medicine and rehabilitation, psychological medicine, pulmonology, and rheumatology. It also provides preventive health check-ups. In addition, the company operates a medical college that provides postgraduate programs in neurology, pediatrics, psychiatry, orthopedics, and cardiopulmonary care. It serves out-patients, in-patients, and the common public. Kovai Medical Center and Hospital Limited was incorporated in 1985 and is based in Coimbatore, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. S. Karthikeyan
Headquarters
Coimbatore
Employees
6,885
Website
kmchhospitals.comExchange
View on NSE ↗Key stats
Market cap
₹6,812.65 Cr
P/E ratio (TTM)
26.6
Dividend yield
0.25%
EPS (TTM)
₹234.09
Beta (5Y monthly)
0.41
Shares float
45.94 L
EPS · quarter ended Jun 2026
₹63.14
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 6.3% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹690.36 Cr | ₹906.00 Cr | ₹958.19 Cr | ₹1,133.84 Cr | ₹1,369.74 Cr | ₹1,584.15 Cr | |
| EBITDA | ₹205.07 Cr | ₹269.34 Cr | ₹284.32 Cr | ₹362.48 Cr | ₹407.81 Cr | ₹467.05 Cr |
| ₹77.69 Cr | ₹104.26 Cr | ₹115.77 Cr | ₹179.73 Cr | ₹208.95 Cr | ₹244.46 Cr | |
| Diluted EPS | — | — | — | ₹164.25 | ₹190.95 | ₹223.41 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,281.15 Cr | ₹1,342.66 Cr | ₹1,438.12 Cr | ₹1,438.23 Cr | ₹1,799.91 Cr | ₹2,066.08 Cr | |
| — | ₹550.19 Cr | ₹510.91 Cr | ₹310.36 Cr | ₹415.34 Cr | ₹402.75 Cr | |
| Stockholders' equity | ₹510.00 Cr | ₹609.31 Cr | ₹719.04 Cr | ₹888.54 Cr | ₹1,086.16 Cr | ₹1,319.27 Cr |
Current assets, Trade receivables, Non-current assets, CWIP, Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹262.91 Cr | ₹344.13 Cr | ₹334.61 Cr | ₹361.83 Cr | |
| Investing cash flow | — | — | ₹-126.86 Cr | ₹-138.17 Cr | ₹-333.83 Cr | ₹-230.18 Cr |
| — | — | ₹-85.70 Cr | ₹-243.49 Cr | ₹62.09 Cr | ₹-58.37 Cr | |
| Capital expenditure | — | — | ₹-127.40 Cr | ₹-138.42 Cr | ₹-353.10 Cr | ₹-251.95 Cr |
| End cash position | — | — | ₹17.95 Cr | ₹59.60 Cr | ₹14.30 Cr | ₹63.72 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Kovai Medical Center & Hospital Limited | ₹6,687.91 Cr | ₹6,226 | 26.1 | 5.07 | 18.5% | 0.31 | +15.7% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 29
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
8 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Kovai Medical Center & Hospital (KOVAI.NS) Edges Up 0.39% to ₹6,112, Holding Above Key Support - Linear Regression
siam.in · 2 days ago